Emerging biomimetic biopolymer-based composites: advancing accessible and sustainable neural disease models and therapeutics
Duc D., Pattem J., Gambrill B., Prokopovich P., Kocatürkmen A., Church M.
Narrative Review, published in Front Bioeng Biotechnol (2025) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Narrative Review
- Journal
- Front Bioeng Biotechnol (2025)
- Reported sample size
- —
- Source database
- Europe PMC
- PMID
- 41797816
- PMCID
- PMC12960564
- DOI
- 10.3389/fbioe.2025.1720254
- Citations
- 1
Abstract (original English)
Neurological diseases are leading causes of death globally and disability-adjusted life years (DALYs) globally. Because of this, urgency in providing technologies and essential medicines to tackle this issue is currently recognized as key in reversing this trend. Global health strategies have recognized tissue engineering as a pillar element in progressing both neurological disease research and therapy discovery. Over time, various biomaterials have been developed with a few barriers appearing along the way when considering translation for routine neurological disorders research and therapy. These barriers include accessibility, sustainability, cost-effectiveness and affordability. In this review, we discuss how biopolymers, namely biomimetic advanced biopolymers composites have emerged to answer this issue. We will explore various types of biomimetic nanocellulose-based, self-assembling peptides, glycosaminoglycan composite, advanced functionalized nanoparticles amongst others are used to create a range of innovative state-of -the-art neuronal models that can be employed for neuronal disease investigation and therapy. Finally, we will review the current factors enabling and hindering their translation and scalability (e.g. manufacturing, characterization and commercialization) and provide a Research and Development Roadmap that can be explored to facilitate their development a
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.